The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

H. Miles Prince Haematology Service, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; University of Melbourne, Parkville, VIC, AustraliaCorrespondence[email protected]

Mark Bishton Haematology Service, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Simon Harrison Haematology Service, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Abstract

Preclinical evidence supports the investigation of histone deacetylase inhibitors for the treatment of myeloma. Results from early studies demonstrate clinical activity and further studies investigating combination strategies should be explored.

Keywords:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

Information for

Open access

Opportunities

Help and information

The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature